

CITATION REPORT

List of articles citing

Accumulation of toxic α -synuclein oligomer within endoplasmic reticulum occurs in α -synucleinopathy in vivo

DOI: 10.1523/jneurosci.5368-11.2012

Journal of Neuroscience, 2012, 32, 3301-5.

Source: <https://exaly.com/paper-pdf/52423062/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
255	Neurodegenerative disease: The stress of misfolding. 2012 , 11, 352-3		1
254	The stress of misfolding. 2012 , 13, 290		2
253	Systematic mutagenesis of β synuclein reveals distinct sequence requirements for physiological and pathological activities. <i>Journal of Neuroscience</i> , 2012 , 32, 15227-42	6.6	119
252	Do β synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?. 2012 , 237, 36-42		24
251	Endoplasmic reticulum stress is important for the manifestations of β synucleinopathy in vivo. <i>Journal of Neuroscience</i> , 2012 , 32, 3306-20	6.6	267
250	From β synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. 2012 , 1476, 183-202		75
249	Evolution of neurodegeneration. 2012 , 22, R753-61		15
248	Hormesis: protecting neurons against cellular stress in Parkinson disease. 2012 , 8, 997-1001		60
247	The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. 2013 , 1, 31		104
246	Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies. 2013 , 1, 79		58
245	Off-pathway β synuclein oligomers seem to alter β synuclein turnover in a cell model but lack seeding capability in vivo. 2013 , 20, 233-44		18
244	Nasal inoculation with β synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine. 2013 , 243, 205-12		12
243	The many faces of β synuclein: from structure and toxicity to therapeutic target. 2013 , 14, 38-48		975
242	β synuclein oligomers and clinical implications for Parkinson disease. 2013 , 73, 155-69		209
241	An ERcentric view of Parkinson's disease. 2013 , 19, 165-75		148
240	Monoclonal antibodies selective for β synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and β synuclein transgenic mice with the disease-causing A30P mutation. 2013 , 126, 131-44		65
239	Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. 2013 , 91, 693-703		47

238	Characterizing the dynamics of β synuclein oligomers using hydrogen/deuterium exchange monitored by mass spectrometry. 2013 , 52, 9097-103		43
237	Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. 2013 , 3, 415-59		58
236	Crosstalk between Endoplasmic Reticulum Stress and Protein Misfolding in Neurodegenerative Diseases. 2013 , 2013, 1-22		33
235	Parallel mechanisms for direct and indirect membrane protein trafficking by synucleins. 2013 , 6, e26794		4
234	Amyloidogenic Protein of β Synuclein. 2013 , 33, 123		1
233	Extracellular β synuclein leads to microtubule destabilization via GSK-3 β -dependent Tau phosphorylation in PC12 cells. <i>PLoS ONE</i> , 2014 , 9, e94259	3-7	52
232	Accumulation of the sigma-1 receptor is common to neuronal nuclear inclusions in various neurodegenerative diseases. 2014 , 34, 148-58		43
231	GRP78 clustering at the cell surface of neurons transduces the action of exogenous alpha-synuclein. 2014 , 21, 1971-83		47
230	Noninvasive bioluminescence imaging of β synuclein oligomerization in mouse brain using split firefly luciferase reporters. <i>Journal of Neuroscience</i> , 2014 , 34, 16518-32	6.6	19
229	Targeting β Synuclein as a Parkinson's Disease Therapeutic. 2014 , 43-109		
228	Docosahexaenoic acid reduces ER stress and abnormal protein accumulation and improves neuronal function following traumatic brain injury. <i>Journal of Neuroscience</i> , 2014 , 34, 3743-55	6.6	90
227	Structure activity relationship of phenolic acid inhibitors of β synuclein fibril formation and toxicity. 2014 , 6, 197		78
226	Gallic acid interacts with β synuclein to prevent the structural collapse necessary for its aggregation. 2014 , 1844, 1481-5		71
225	Integrating pathways of Parkinson's disease in a molecular interaction map. 2014 , 49, 88-102		178
224	Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. 2014 , 130, 59-72		102
223	Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. 2014 , 15, 233-49		469
222	Glucocerebrosidase is shaking up the synucleinopathies. 2014 , 137, 1304-22		113
221	Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. 2014 , 111, 6804-9		141

220	Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. 2014 , 21, 396-413	670
219	DJ-1 interactions with β -synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. 2014 , 5, e1350	106
218	Biophysical groundwork as a hinge to unravel the biology of β -synuclein aggregation and toxicity. 2014 , 47, 1-48	30
217	β -Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. <i>Neurobiology of Disease</i> , 2014 , 70, 149-61	7.5 70
216	Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. 2014 , 251, 22-9	66
215	Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways. 2015 , 16, 69	44
214	Altered machinery of protein synthesis is region- and stage-dependent and is associated with β -synuclein oligomers in Parkinson's disease. 2015 , 3, 76	60
213	Targeting the endoplasmic reticulum in prion disease treatment: breakthroughs and challenges. 2015 , 31	1
212	Seeking a mechanism for the toxicity of oligomeric β -synuclein. <i>Biomolecules</i> , 2015 , 5, 282-305	5.9 132
211	β -Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease. <i>Biomolecules</i> , 2015 , 5, 2675-700	5.9 33
210	Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. 2015 , 9, 59	77
209	The unfolded protein response in multiple sclerosis. 2015 , 9, 264	48
208	Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinson's Disease. 2015 , 9, 433	45
207	Identification of synaptosomal proteins binding to monomeric and oligomeric β -synuclein. <i>PLoS ONE</i> , 2015 , 10, e0116473	3.7 50
206	Distinct higher-order β -synuclein oligomers induce intracellular aggregation. 2015 , 468, 485-93	23
205	Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. 2015 , 138, 1642-57	159
204	The phosphorylation of β -synuclein: development and implication for the mechanism and therapy of the Parkinson's disease. 2015 , 135, 4-18	49
203	Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease. 2015 , 589, 3739-48	51

202	Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory. 2015 , 41, 414-27		56
201	A53T human β synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. <i>Journal of Neuroscience</i> , 2015 , 35, 890-905	6.6	112
200	The neuroprotective effect of salubrinal in a mouse model of traumatic brain injury. 2015 , 17, 58-70		53
199	β Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson's disease. <i>Neurobiology of Disease</i> , 2015 , 76, 112-125	7.5	70
198	The loss of glucose-regulated protein 78 (GRP78) during normal aging or from siRNA knockdown augments human alpha-synuclein (β Syn) toxicity to rat nigral neurons. 2015 , 36, 2213-23		43
197	Increased oligomerization and phosphorylation of β synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains. 2015 , 36, 2649-59		44
196	Inhibition of Cytohesins Protects against Genetic Models of Motor Neuron Disease. <i>Journal of Neuroscience</i> , 2015 , 35, 9088-105	6.6	10
195	PGC-1 β activity in nigral dopamine neurons determines vulnerability to β synuclein. 2015 , 3, 16		53
194	Inhibition of Eukaryotic Initiation Factor 2 Alpha Phosphatase Reduces Tissue Damage and Improves Learning and Memory after Experimental Traumatic Brain Injury. 2015 , 32, 1608-20		34
193	DT-Diaphorase Prevents Aminochrome-Induced Alpha-Synuclein Oligomer Formation and Neurotoxicity. 2015 , 145, 37-47		57
192	Parkinson disease mutant E46K enhances β synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo. 2015 , 290, 9412-27		41
191	Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant β synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease. 2015 , 24, 6675-86		61
190	Endoplasmic reticulum stress: relevance and therapeutics in central nervous system diseases. 2015 , 51, 1343-52		65
189	Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity. 2016 , 2016, 7596482		8
188	Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. 2016 , 10, 408		198
187	Aggregated Alpha-Synuclein Transfer Efficiently between Cultured Human Neuron-Like Cells and Localize to Lysosomes. <i>PLoS ONE</i> , 2016 , 11, e0168700	3.7	38
186	Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease. 2016 , 41, 2788-2796		63
185	Cortical phosphorylated β synuclein levels correlate with brain wave spectra in Parkinson's disease. 2016 , 31, 1012-9		19

184	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. 2016 , 31, 771-81		66
183	Protein Partners of β Synuclein in Health and Disease. 2016 , 26, 389-97		28
182	Up-regulation of activating transcription factor 4 induces severe loss of dopamine nigral neurons in a rat model of Parkinson's disease. 2016 , 627, 36-41		33
181	Understanding Dopaminergic Cell Death Pathways in Parkinson Disease. <i>Neuron</i> , 2016 , 90, 675-91	13.9	307
180	Protein aggregation and ER stress. 2016 , 1648, 658-666		64
179	Inhibition of Excessive Oxidative Protein Folding Is Protective in MPP(+) Toxicity-Induced Parkinson's Disease Models. 2016 , 25, 485-97		22
178	Gene therapy to target ER stress in brain diseases. 2016 , 1648, 561-570		28
177	A de novo compound targeting β Synuclein improves deficits in models of Parkinson's disease. 2016 , 139, 3217-3236		76
176	Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. 2016 , 139 Suppl 1, 240-255		95
175	In vitro prion-like behaviour of TDP-43 in ALS. <i>Neurobiology of Disease</i> , 2016 , 96, 236-247	7.5	80
174	Ablation of Perk in Schwann Cells Improves Myelination in the S63del Charcot-Marie-Tooth 1B Mouse. <i>Journal of Neuroscience</i> , 2016 , 36, 11350-11361	6.6	17
173	Novel Therapeutic Approaches to the Treatment of Parkinson's Disease. 2016 ,		
172	A familial ATP13A2 mutation enhances alpha-synuclein aggregation and promotes cell death. 2016 , 25, 2959-2971		19
171	Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system. <i>Neurobiology of Disease</i> , 2016 , 88, 44-54	7.5	16
170	Smoking-Relevant Nicotine Concentration Attenuates the Unfolded Protein Response in Dopaminergic Neurons. <i>Journal of Neuroscience</i> , 2016 , 36, 65-79	6.6	32
169	Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo. 2016 , 71, 92-101		12
168	The Role of the Protein Quality Control System in SBMA. 2016 , 58, 348-64		25
167	Cellular Uptake of β Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of β Synuclein and Mediated via Fc γ Receptors. 2017 , 37, 121-131		22

166	Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson's Disease and Dementia with Lewy Bodies. 2017 , 27, 3-12	44
165	Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia. 2017 , 37, 1910-1926	35
164	Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated β Synuclein-selective Autophagic Degradation. 2017 , 292, 3919-3928	16
163	β Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. 2017 , 23, 1-13	452
162	Translating protein phosphatase research into treatments for neurodegenerative diseases. 2017 , 45, 101-112	5
161	Parkinson's disease. 2017 , 157-174	2
160	Selective lowering of synapsins induced by oligomeric β Synuclein exacerbates memory deficits. 2017 , 114, E4648-E4657	34
159	β Synuclein Oligomers: A Study in Diversity. 2017 , 57, 699-723	12
158	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy. 2017 , 133, 283-301	31
157	Structural Characteristics of β Synuclein Oligomers. 2017 , 329, 79-143	57
156	Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management. 2017 , 40, 149-167	37
155	ER Stress and Neurodegenerative Disease: A Cause or Effect Relationship?. 2018 , 414, 131-157	18
154	CDK5-mediated phosphorylation of XBP1s contributes to its nuclear translocation and activation in MPP-induced Parkinson's disease model. 2017 , 7, 5622	9
153	Alpha-synuclein oligomers: a new hope. 2017 , 134, 819-838	153
152	Endoplasmic reticulum stress and inflammation in the central nervous system. 2017 , 12, 42	110
151	Protein folding by NMR. 2017 , 100, 52-77	30
150	Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells. 2017 , 7, 16158	31
149	The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance. 2017 , 10, 187	84

148	The Contribution of α -Synuclein Spreading to Parkinson's Disease Synaptopathy. 2017 , 2017, 5012129		46
147	The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. <i>PLoS ONE</i> , 2017 , 12, e0184262	3.7	12
146	Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease. 2018 , 12, 10-19		3
145	Seipin deficiency in mice causes loss of dopaminergic neurons via aggregation and phosphorylation of α -synuclein and neuroinflammation. 2018 , 9, 440		9
144	Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2018 , 112, 136-148	7.5	85
143	Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. 2018 , 24, 540-559		59
142	Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. <i>Neurobiology of Disease</i> , 2018 , 112, 106-118	7.5	86
141	Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons. <i>Neurobiology of Disease</i> , 2018 , 111, 36-47	7.5	17
140	D409H GBA1 mutation accelerates the progression of pathology in A53T α -synuclein transgenic mouse model. 2018 , 6, 32		16
139	Impact of membrane curvature on amyloid aggregation. 2018 , 1860, 1741-1764		48
138	Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. 2018 , 19,		48
137	When nature's robots go rogue: exploring protein homeostasis dysfunction and the implications for understanding human aging disease pathologies. 2018 , 15, 293-309		4
136	Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. <i>Neurobiology of Disease</i> , 2018 , 109, 249-257	7.5	275
135	Association Between Pathology and Electroencephalographic Activity in Parkinson's Disease. 2018 , 49, 321-327		2
134	Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α -synuclein mouse model of Parkinson's disease. 2018 , 9, 6414-6426		48
133	Reduced Cytosolic Calcium as an Early Decisive Cellular State in Parkinson's Disease and Synucleinopathies. 2018 , 12, 819		10
132	α -Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models. 2018 , 10, 1759091418812587		
131	Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. 2018 , 22, 833-848		52


130	Exploring the role of methionine residues on the oligomerization and neurotoxic properties of DOPAL-modified β synuclein. 2018 , 505, 295-301		7
129	Chaperone AMPylation modulates aggregation and toxicity of neurodegenerative disease-associated polypeptides. 2018 , 115, E5008-E5017		14
128	Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation. 2018 ,		3
127	Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified β synuclein oligomers. 2018 , 1864, 3060-3068		5
126	ELISA method to detect β synuclein oligomers in cell and animal models. <i>PLoS ONE</i> , 2018 , 13, e0196056	3.7	29
125	Non-cell-autonomous actions of β synuclein: Implications in glial synucleinopathies. 2018 , 169, 158-171		12
124	Determinants of dopaminergic neuron loss in Parkinson's disease. 2018 , 285, 3657-3668		127
123	Could a Common Mechanism of Protein Degradation Impairment Underlie Many Neurodegenerative Diseases?. 2018 , 12, 1179069518794675		16
122	β synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. 2019 , 150, 522-534		99
121	Infectious Etiologies of Parkinsonism: Pathomechanisms and Clinical Implications. <i>Frontiers in Neurology</i> , 2019 , 10, 652	4.1	59
120	IRE1 promotes neurodegeneration through autophagy-dependent neuron death in the <i>Drosophila</i> model of Parkinson's disease. 2019 , 10, 800		20
119	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019 , 8, 28	10.3	42
118	Glucocerebrosidase and its relevance to Parkinson disease. 2019 , 14, 36		96
117	β synuclein: A Multifunctional Player in Exocytosis, Endocytosis, and Vesicle Recycling. 2019 , 13, 28		34
116	GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson's Disease Patients. 2019 , 13, 697		13
115	Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of β synucleinopathy. 2019 , 138, 551-574		28
114	Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO- β synuclein-A53T mouse model, correlating with increased nitration and aggregation of β synuclein and exacerbation of motor impairment. 2019 , 141, 115-140		18
113	Sleep, Aging, and Cellular Health: Aged-Related Changes in Sleep and Protein Homeostasis Converge in Neurodegenerative Diseases. 2019 , 11, 140		10

112	Linking the Endoplasmic Reticulum to Parkinson's Disease and Alpha-Synucleinopathy. 2019 , 13, 560		49
111	Antibodies against alpha-synuclein: tools and therapies. 2019 , 150, 612-625		27
110	Alpha-Synuclein Is a Target of Fic-Mediated Adenylation/AMPylation: Possible Implications for Parkinson's Disease. 2019 , 431, 2266-2282		15
109	Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease. 2019 , 29, 813-825		18
108	Dysfunction of Cellular Proteostasis in Parkinson's Disease. 2019 , 13, 457		54
107	Microbiome, Parkinson's Disease and Molecular Mimicry. <i>Cells</i> , 2019 , 8,	7.9	43
106	CDNF Protein Therapy in Parkinson's Disease. 2019 , 28, 349-366		36
105	Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. 2019 , 137, 455-466		30
104	Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. <i>Translational Neurodegeneration</i> , 2019 , 8, 5	10.3	28
103	Endoplasmic Reticulum Stress: Implications for Neuropsychiatric Disorders. 2019 , 55, 8-19		14
102	Cellular α -Synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons. 2019 , 28, 2001-2013		55
101	Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. 2019 , 12, 299		91
100	Cellular Proteostasis in Neurodegeneration. 2019 , 56, 3676-3689		79
99	Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	28
98	The unfolded protein response in neurodegenerative disorders - therapeutic modulation of the PERK pathway. 2019 , 286, 342-355		74
97	The Integrated Stress Response and Phosphorylated Eukaryotic Initiation Factor 2 in Neurodegeneration. 2020 , 79, 123-143		23
96	Transient parkinsonism associated with acute Legionnaires' disease. 2020 , 13,		
95	The Role of Lipids in the Initiation of α -Synuclein Misfolding. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 562241	5.7	10

94	Phase Separation and Neurodegenerative Diseases: A Disturbance in the Force. 2020 , 55, 45-68		70
93	The Role of β Synuclein Oligomers in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	31
92	Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies. 2020 , 72, 1195-1217		12
91	Linking Alpha-Synuclein to the Actin Cytoskeleton: Consequences to Neuronal Function. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 787	5.7	6
90	Reversal of Alpha-Synuclein Fibrillization by Protein Disulfide Isomerase. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 726	5.7	2
89	Alpha-Synuclein FRET Biosensors Reveal Early Alpha-Synuclein Aggregation in the Endoplasmic Reticulum. <i>Life</i> , 2020 , 10,	3	6
88	Soluble endogenous oligomeric β Synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk. 2020 , 10, 791-818		23
87	"LRRK2: Autophagy and Lysosomal Activity". 2020 , 14, 498		27
86	The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	21
85	Mechanisms of alpha-synuclein toxicity: An update and outlook. 2020 , 252, 91-129		28
84	Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles. 2019 , 13, 1399		37
83	Endoplasmic reticulum stress, an important factor in the development of Parkinson's disease. 2020 , 324, 20-29		23
82	Lipids Nutrients in Parkinson and Alzheimer's Diseases: Cell Death and Cytoprotection. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
81	Targeting endoplasmic reticulum stress and autophagy as therapeutic approaches for neurological diseases. 2020 , 350, 285-325		14
80	Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: Virus-based models versus inoculation of exogenous preformed toxic species. 2020 , 338, 108685		8
79	β Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. 2020 , 15, 27		16
78	Nuclear Factor- κ B Dysregulation and β Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease. 2020 , 12, 68		25
77	Protective effects of saponins from <i>Panax japonicus</i> on neurons of the colon myenteric plexus in aging rats through reduction of β Synuclein through endoplasmic reticulum stress. 2021 , 21, 85-93		0

76	Cytisine is neuroprotective in female but not male 6-hydroxydopamine lesioned parkinsonian mice and acts in combination with 17- β -estradiol to inhibit apoptotic endoplasmic reticulum stress in dopaminergic neurons. 2021 , 157, 710-726		4
75	Oxyresveratrol exerts ATF4- and Grp78-mediated neuroprotection against endoplasmic reticulum stress in experimental Parkinson's disease. 2021 , 24, 181-196		7
74	Ndfip1 Prevents Rotenone-Induced Neurotoxicity and Upregulation of β Synuclein in SH-SY5Y Cells. 2020 , 13, 613404		2
73	Parkinson's disease. 2021 , 1-171		1
72	Activation of α -nAChRs Promotes the Clearance of β Synuclein and Protects Against Apoptotic Cell Death Induced by Exogenous β Synuclein Fibrils. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 637319	5.7	0
71	REST Protects Dopaminergic Neurons from Mitochondrial and β Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model. <i>Journal of Neuroscience</i> , 2021 , 41, 3731-3746	6.6	6
70	PERK Pathway and Neurodegenerative Disease: To Inhibit or to Activate?. <i>Biomolecules</i> , 2021 , 11,	5.9	8
69	Pre-differentiation exposure to low-dose of atrazine results in persistent phenotypic changes in human neuronal cell lines. 2021 , 271, 116379		8
68	The Function of the Metals in Regulating Epigenetics During Parkinson's Disease. 2020 , 11, 616083		2
67	Biomarkers and the Role of β Synuclein in Parkinson's Disease. 2021 , 13, 645996		5
66	Astaxanthin suppresses endoplasmic reticulum stress and protects against neuron damage in Parkinson's disease by regulating miR-7/SNCA axis. 2021 , 165, 51-60		11
65	NMR unveils an N-terminal interaction interface on acetylated- β Synuclein monomers for recruitment to fibrils. 2021 , 118,		9
64	Changes in Drp1 Function and Mitochondrial Morphology Are Associated with the β Synuclein Pathology in a Transgenic Mouse Model of Parkinson's Disease. <i>Cells</i> , 2021 , 10,	7.9	6
63	Cell-type-specific disruption of PERK-eIF2 β signaling in dopaminergic neurons alters motor and cognitive function. 2021 ,		4
62	Role of Polyphenols on Gut Microbiota and the Ubiquitin-Proteasome System in Neurodegenerative Diseases. 2021 , 69, 6119-6144		7
61	Neurons and Glia Interplay in β Synucleinopathies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
60	"Janus-Faced" β Synuclein: Role in Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 673395	5.7	3
59	Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease: The Emerging Role of VDAC. <i>Biomolecules</i> , 2021 , 11,	5.9	7

58	The Cross-Links of Endoplasmic Reticulum Stress, Autophagy, and Neurodegeneration in Parkinson's Disease. 2021 , 13, 691881		12
57	FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics. 2021 , 12, 675725		2
56	Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors. <i>Npj Parkinsons Disease</i> , 2021 , 7, 52	9.7	6
55	T-Type Ca Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
54	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinsons Disease</i> , 2021 , 7, 65	9.7	12
53	Visualization of early oligomeric β synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P] β syn transgenic mouse model. <i>Journal of Neuroscience Research</i> , 2021 , 99, 2525-2539	4.4	0
52	Roles for β synuclein in Gene Expression. <i>Genes</i> , 2021 , 12,	4.2	2
51	Parkinson's Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 707441	5.7	2
50	All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. <i>Cells</i> , 2021 , 10,	7.9	2
49	Cerebral dopamine neurotrophic factor reduces β synuclein aggregation and propagation and alleviates behavioral alterations in vivo. <i>Molecular Therapy</i> , 2021 , 29, 2821-2840	11.7	8
48	Perspective: Modulating the integrated stress response to slow aging and ameliorate age-related pathology.. <i>Nature Aging</i> , 2021 , 1, 760-768		3
47	A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1131, 131-161	3.6	17
46	CHAPTER 8:Synuclein and Parkinson's Disease: An Update. <i>RSC Drug Discovery Series</i> , 2013 , 175-216	0.6	6
45	NMR unveils an N-terminal interaction interface on acetylated- β synuclein monomers for recruitment to fibrils.		1
44	Activation of tyrosine kinase c-Abl contributes to β synuclein-induced neurodegeneration. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2970-88	15.9	88
43	Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. <i>PLoS ONE</i> , 2013 , 8, e70872	3.7	27
42	Autophagy prevents hippocampal β synuclein oligomerization and early cognitive dysfunction after anesthesia/surgery in aged rats. <i>Aging</i> , 2020 , 12, 7262-7281	5.6	12
41	Age- and brain region-dependent β synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating β synuclein phosphorylation in aging monkey brains. <i>Oncotarget</i> , 2016 , 7, 8466-80	3.3	21

40	Subcellular localization of alpha-synuclein aggregates and their interaction with membranes. <i>Neural Regeneration Research</i> , 2018 , 13, 1136-1144	4.5	32
39	Examining the Toxicity of β Synuclein in Neurodegenerative Disorders. <i>Life</i> , 2021 , 11,	3	0
38	Endoplasmic Reticulum-Based Calcium Dysfunctions in Synucleinopathies. <i>Frontiers in Neurology</i> , 2021 , 12, 742625	4.1	0
37	DJ-1 Acts as a Scavenger of β Synuclein Oligomers and Restores Monomeric Glycated β Synuclein. <i>Biomolecules</i> , 2021 , 11,	5.9	0
36	 <i>Biologischeske Membrany</i> , 2017 , 4-14	0.1	
35	Endoplasmic reticulum, oxidative stress and their complex crosstalk in neurodegeneration: proteostasis, signaling pathways and molecular chaperones. <i>AIMS Molecular Science</i> , 2017 , 4, 424-444	0.9	1
34	Chaperone AMPylation modulates aggregation and toxicity of neurodegenerative disease-associated polypeptides.		0
33	Alpha-Synuclein is a Target of Fic-mediated Adenylylation/AMPylation: Implications for Parkinson's Disease.		0
32	Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. <i>MAbs</i> , 2021 , 13, 1994690	6.6	0
31	THE PATHOGENETIC ASPECTS OF PARKINSON'S DISEASE AND POSSIBLE WAYS OF THEIR CORRECTION. <i>Modern Medical Technologies</i> , 2020 , 47,	0	
30	Genetic reduction of PERK-eIF2 β signaling in dopaminergic neurons drives cognitive and age-dependent motor dysfunction.		
29	Fibroblast growth factor 1 attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson's disease. <i>American Journal of Translational Research (discontinued)</i> , 2014 , 6, 664-77	3	18
28	Alpha-synuclein oligomerization increases its effect on promoting NMDA receptor internalization. <i>International Journal of Clinical and Experimental Pathology</i> , 2019 , 12, 87-100	1.4	2
27	Rescue of β Synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking. <i>Neuron</i> , 2021 ,	13.9	5
26	β Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox. <i>Cell and Bioscience</i> , 2021 , 11, 196	9.8	1
25	Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
24	Proteostasis impairment and ER stress as a possible target to treat Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021 , 2, 245-260		
23	Intermediates of β Synuclein aggregation: Implications in Parkinson's disease pathogenesis.. <i>Biophysical Chemistry</i> , 2021 , 281, 106736	3.5	5

22	Upregulation of β synuclein following immune activation: Possible trigger of Parkinson's disease.. <i>Neurobiology of Disease</i> , 2022 , 166, 105654	7.5	3
21	Immunotherapeutic interventions in Parkinson's disease: Focus on β synuclein.. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022 , 129, 381-433	5.3	0
20	Current Progress in the Development of Probes for Targeting β synuclein Aggregates.. <i>ACS Chemical Neuroscience</i> , 2022 ,	5.7	0
19	Extracellular alpha-synuclein: Sensors, receptors, and responses.. <i>Neurobiology of Disease</i> , 2022 , 168, 105696	7.5	1
18	Image_1.TIF. 2021 ,		
17	Genetic variations in EIF2AK3 are associated with neurocognitive impairment in people living with HIV.		
16	Reduction of β YN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. <i>Pharmaceutics</i> , 2022 , 14, 1412	6.4	0
15	Loss of tau expression attenuates neurodegeneration associated with β synucleinopathy. <i>Translational Neurodegeneration</i> , 2022 , 11,	10.3	0
14	Harmol promotes β synuclein degradation and improves motor impairment in Parkinson's models via regulating autophagy-lysosome pathway. 2022 , 8,		0
13	Molecular Insights into the Role of ER Stress in Neurodegenerative Diseases. 2022 , 219-249		0
12	Small soluble β synuclein aggregates are the toxic species in Parkinson's disease. 2022 , 13,		2
11	EGCG has Dual and Opposing Effects on the N-terminal Region of Self-associating β synuclein Oligomers. 2022 , 434, 167855		1
10	Mendelian Randomization Analysis Reveals No Causal Relationship Between Plasma β synuclein and Parkinson's Disease.		0
9	The role of the endolysosomal pathway in β synuclein pathogenesis in Parkinson's disease. 16,		0
8	Simultaneous Determination of Size and Shape of Single β synuclein Oligomers in Solution.		0
7	Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress. 2023 , 24, 2381		0
6	Deficiency of RAB39B Activates ER Stress-Induced Pro-apoptotic Pathway and Causes Mitochondrial Dysfunction and Oxidative Stress in Dopaminergic Neurons by Impairing Autophagy and Upregulating β synuclein.		0
5	Unraveling the Complex Interplay between Alpha-Synuclein and Epigenetic Modification. 2023 , 24, 6645		0

- 4 The Role of α -Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features. **2023**, 11, 541
- 3 Potential roles of the endoplasmic reticulum stress pathway in amyotrophic lateral sclerosis. 15,
- 2 Role of Astrocytes in Parkinson's Disease Associated with Genetic Mutations and Neurotoxicants. **2023**, 12, 622
- 1 Nanoscale imaging of individual amyloid aggregates extracted from brains of Alzheimer and Parkinson patients reveals presence of lipids in α -Synuclein but not in amyloid β fibrils. **2023**, 32,